Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/57465
Title: Radiotherapy Results in Locally Advanced Sinonasal Cancer: Turkish Society for Radiation Oncology, Head and Neck Study Group 01-005
Authors: Duru, Birgi, S.
Ozkaya, Akagündüz, O.
Dagdelen, M.
Yazici, G.
Canyilmaz, E.
Ceylaner, Biçakçi, B.
Çetinayak, H.O.
Keywords: chemoradiotherapy
intensity-modulated radiotherapy
paranasal sinus cancer
surgery
cisplatin
adult
advanced cancer
aged
Article
cancer chemotherapy
cancer patient
cancer prognosis
cancer radiotherapy
cancer staging
cancer surgery
cohort analysis
Common Terminology Criteria for Adverse Events
distant metastasis free survival
ECOG Performance Status
female
follow up
human
intensity modulated radiation therapy
local recurrence free survival
lymph node
major clinical study
male
maxillary sinus tumor
multiple cycle treatment
overall survival
patient
progression free survival
retrospective study
sinonasal cancer
surgical margin
survival analysis
survival rate
treatment outcome
Turkey (republic)
clinical trial
intensity modulated radiation therapy
middle aged
mortality
multicenter study
paranasal sinus tumor
pathology
procedures
radiation oncology
radiotherapy
treatment outcome
turkey (bird)
very elderly
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Paranasal Sinus Neoplasms
Radiation Oncology
Radiotherapy, Intensity-Modulated
Retrospective Studies
Survival Rate
Treatment Outcome
Turkey
Publisher: Lippincott Williams and Wilkins
Abstract: Objectives: This study aims to examine the treatment outcomes and related factors in locally advanced sinonasal cancer across Turkiye. Methods: Twelve centers participants of the Turkish Society for Radiation Oncology Head and Neck Study Group attended the study. One hundred and ninety-four patients treated with intensity-modulated radiation therapy between 2001 and 2021 were analyzed retrospectively. The survival analysis was performed using the Kaplan-Meier method. Acute and late toxicity were recorded per Common Toxicity Criteria for Adverse Events V4.0. Results: The median age was 58 years and 70% were male. The majority of tumors were located in maxillary sinus (59%). Most of the patients (%83) had T3 and T4A disease. Fifty-three percent of patients were in stage 4A. Radiotherapy was administered to 80% of the patients in the adjuvant settings. Median 66 Gy dose was administered in median 31 fractions. Chemotherapy was administered concomitantly with radiotherapy in 45% of the patients mostly with weekly cisplatin. No grade ≥4 acute and late toxicity was observed. The median follow-up was 43 months. The 5-year and 10-year overall survival (OS); locoregional recurrence-free survival (LRFS); distant metastasis-free survival (DMFS), and progression-free survival (PFS) rates were 61% and 47%; 69% and 61%; 72%, and 69%, and 56% and 49%, respectively. In the multivariate analysis, several factors demonstrated significant influence on OS, such as performance status, surgery, and lymph node involvement. Moreover, surgery was the key prognostic factor for LRFS. For DMFS, lymph node involvement and surgical margin were found to be influential factors. In addition, performance status and lymph node involvement were identified as significantly affecting PFS. Conclusions: In our study, the authors obtained promising results with IMRT. Performance status, lymph node involvement, and surgery emerged as the primary factors significantly influencing OS. © 2024 Lippincott Williams and Wilkins. All rights reserved.
URI: https://doi.org/10.1097/COC.0000000000001089
https://hdl.handle.net/11499/57465
ISSN: 0277-3732
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection

Show full item record



CORE Recommender

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.